Under the authority of FAR 6.302-1, the U.S. Army, RDECOM, Natick Contracting Division, Kansas Street, Natick, MA, on behalf of the Naval Health Research Center, intends to negotiate and award a contract to GenPhar, Inc. of 600 Seacoast Parkway, Mount Pleasant, South Carolina. GenPhar, Inc. is the only producer and supplier of the dengue vaccine formulation based on a complex adenovirus vector, for use in a human clinical vaccine trial, which was developed in close collaboration with Naval Medical Research Center (NMRC) requirements over the last three years. GenPhar, Inc. currently holds the patent for the dengue vaccine. Requirements include, but not limited to, a formulation mixture of two vaccine constructs expressing antigens from each of the four serotypes (dengue 1, 2, 3 & 4), which are consistent with previous batches to ensure reproducibility of data generated between studies already carried out by investigators within the NMRC program. This notice of intent is not a request for competitive quotes. No solicitation document is available and telephone requests will not be accepted. However, any firm that determines it can meet the requirements may give written notice to the Contract Specialist within fifteen (15) calendar days from the date of publication of this synopsis. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirements. This information can be emailed to the Contract Specialist, [email protected]. Responses will be evaluated; however, a determination by the government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the government. This synopsis expires 21 July 2008 at 10:00 EST.

Bid Protests Not Available